Department of Dermatology, Venereology, and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, and Center of Excellence in Dermatology, Mannheim, Germany.
Section of Clinical and Molecular Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
BMC Cancer. 2023 May 13;23(1):436. doi: 10.1186/s12885-023-10912-4.
Liver metastasis is a poor prognostic factor for treatment of advanced cutaneous melanoma with either immunotherapy or targeted therapies. In this study we focused on NRAS mutated melanoma, a cohort with high unmet clinical need.
WT31 melanoma was repeatedly passaged over the liver after intravenous injections five times generating the subline WT31_P5IV. The colonization of target organs, morphology, vascularization and the gene expression profiles of metastases were analyzed.
After intravenous injection lung metastasis was significantly decreased and a trend towards increased liver metastasis was detected for WT31_P5IV as compared to parental WT31. Besides, the ratio of lung to liver metastases was significantly smaller. Histology of lung metastases revealed reduced proliferation of WT31_P5IV in relation to WT31 while both size and necrotic areas were unaltered. Liver metastases of both sublines showed no differences in vascularization, proliferation or necrosis. To identify tumor-intrinsic factors that altered the metastatic pattern of WT31_P5IV RNA sequencing was performed and revealed a differential regulation of pathways involved in cell adhesion. Ex vivo fluorescence imaging confirmed that initial tumor cell retention in the lungs was significantly reduced in WT31_P5IV in comparison to WT31.
This study demonstrates that tumor-intrinsic properties influencing the metastatic pattern of NRAS mutated melanoma are strongly affected by hepatic passaging and the hematogenous route tumor cells take. It has implications for the clinical setting as such effects might also occur during metastatic spread or disease progression in melanoma patients.
肝转移是晚期皮肤黑色素瘤采用免疫疗法或靶向治疗的预后不良因素。在这项研究中,我们专注于NRAS 突变黑色素瘤,这是一个具有高度未满足临床需求的队列。
WT31 黑色素瘤通过静脉注射五次后在肝脏中反复传代,生成亚系 WT31_P5IV。分析了靶器官的定植、形态、血管生成和转移的基因表达谱。
与亲本 WT31 相比,WT31_P5IV 经静脉注射后肺转移明显减少,肝转移趋势增加。此外,肺与肝转移的比例明显减小。肺转移的组织学显示 WT31_P5IV 的增殖减少,而大小和坏死区域不变。两种亚系的肝转移在血管生成、增殖或坏死方面没有差异。为了确定改变 WT31_P5IV 转移模式的肿瘤内在因素,进行了 RNA 测序,结果显示参与细胞黏附的途径存在差异调节。离体荧光成像证实,与 WT31 相比,WT31_P5IV 中初始肿瘤细胞在肺部的保留显著减少。
这项研究表明,影响 NRAS 突变黑色素瘤转移模式的肿瘤内在特性受肝传代和肿瘤细胞血行途径的强烈影响。这对临床环境具有重要意义,因为这种影响也可能发生在黑色素瘤患者的转移扩散或疾病进展过程中。